SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dumb SEND IT

Dumb SEND IT ($DSIT) is gaining momentum as a community-driven low-cap memecoin on Solana, with investors actively discussing its rapid growth and the developer's commitment to community engagement through frequent airdrops and transparency. Supporters are rallying behind the project's 'dumb send' philosophy, frequently comparing its early-stage potential to other successful runners while focusing on social media trending and viral expansion.

Optical Cable Corp. engages in the business of manufacturing fiber optic and copper data communication cabling and connectivity solutions primarily for the enterprise market and various harsh environment, specialty markets, and the wireless carrier market offering integrated suites of high-quality products which operate as a system solution or seamlessly integrate with other components. Its products include fiber optic and copper cabling, hybrid cabling, fiber optic and copper connectors, specialty fiber optic, copper and hybrid connectors, fiber optic and copper patch cords, pre-terminated fiber optic and copper cable assemblies, racks, cabinets, datacom enclosures, patch panels, face plates, multimedia boxes, fiber optic reels, and other cable and connectivity management accessories. The company was founded on June 10, 1983 and is headquartered in Roanoke, VA.

Optical Cable Corp.

Optical Cable Corp is trending as investors monitor its role in the data center and fiber infrastructure boom, with the community closely tracking potential execution of its strategic partnership with Lightera. While sentiment remains divided between those betting on long-term value from increased fiber demand and those wary of the stock's low-float volatility and historical revenue headwinds, the ticker continues to attract attention during retail momentum cycles.

MGM Resorts International is a holding company, which engages in the ownership and operations of casino resorts. The firm's casino resorts offer gaming, hotel, convention, dining, entertainment, retail, and other resort amenities. It operates through the following business segments: Las Vegas Strip Resorts, Regional Operations, MGM China, and MGM Digital. The Las Vegas Strip Resorts segment operates the following casino resorts: Bellagio, MGM Grand Las Vegas, Mandalay Bay, The Mirage, Luxor, New York-New, Excalibur, Park MGM, and Circus Las Vegas. The Regional Operations segment consists of the following casino resorts: MGM Grand Detroit in Detroit, Michigan, Beau Rivage in Biloxi, Mississippi, Gold Strike Tunica in Tunica, Mississippi, Borgata in Atlantic City, New Jersey, MGM National Harbor in Prince George’s County, Maryland, and MGM Springfield in Springfield, Massachusetts. The MGM China segment includes MGM Macau and MGM Cotai. The MGM Digital segment focuses on the online gaming portfolio, which consists primarily of Leo Vegas, which is headquartered in Sweden and Malta. The company was founded by Kerkor Kerkorian on January 29, 1986 and is headquartered in Las Vegas, NV.

MGM Resorts International

MGM Resorts International is drawing attention following the submission of a significant 2.3 billion dollar proposal for a new casino license in New York, a move seen by the community as a key strategy to expand its East Coast footprint. While investors weigh this regulatory catalyst against broader economic concerns, discussions remain split between the stock's long-term potential in the gaming sector and the immediate impact of market-wide volatility on consumer discretionary spending.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic is experiencing heightened community engagement driven by anticipation surrounding ongoing monthly burn initiatives and the development of new ecosystem projects. Supporters are closely watching the chart for signs of a turnaround, frequently discussing the potential for a long-term recovery and increased utility within the blockchain.

Nomad Foods Ltd. operates as a holding company, which manufactures and sells frozen foods for human consumption. The firm offers its products under the brands LUTOSA, la Cocinera, Birds Eye, Iglo, and Findus. The company was founded by Noam Gottesman and Sir Martin E. Franklin on April 1, 2014 and is headquartered in Woking, the United Kingdom.

Nomad Foods Limited

Nomad Foods is trending as investors weigh its attractive dividend yield, aggressive share buyback programs, and low valuation against sector-wide headwinds and concerns about debt levels. The community is actively debating whether these factors signal a deep-value opportunity or a long-term value trap in the frozen food space.

NXP Semiconductors NV is a holding company which engages in the provision of semiconductor solutions. It operates through the following geographical segments: China, Netherlands, United States, Singapore, Germany, Japan, South Korea, Malaysia, and Other Countries. The company was founded on August 2, 2006, and is headquartered in Eindhoven, the Netherlands.

NXP Semiconductors NV

NXP Semiconductors is trending as investors weigh its role as a "picks-and-shovels" play in the automotive and industrial AI buildout against recent analyst downgrades citing inventory and demand concerns. The community is actively debating whether its recent price action signals a long-term value opportunity or a trap amid broader volatility in the semiconductor sector.

The Aircoin memecoin was born from a viral Twitter post from March, 2014 which proclaimed the following:   Evolution: 1. Aircoin 2. Fartcoin 3. Artcoin  Aircoin was launched in August, 2025 and CTO'd twice, with the second CTO team bringing vast experience and expertise to the project. The team includes industry veterans and visual arts professionals.  Aircoin is destined for greatness as a premier memecoin on the BONK.fun platform.

aircoin

The $AIRCOIN community is rallying behind the project's long-term vision, emphasizing its unique 'Airlock' mechanism which has over 38% of the supply locked on-chain to demonstrate deep investor conviction. Supporters frequently highlight the project's historical lore, battle-tested leadership, and growing treasury as key differentiators that position it as a durable, fundamentally-driven alternative to short-lived meme trends.

"What's Updog?" is a Community Led token.

UpDog

UpDog is generating significant community buzz through its long-standing presence on the Solana network, with holders actively promoting its organic growth and whale accumulation trends. The community remains highly engaged by leveraging the project's playful 'dad joke' branding to maintain visibility and momentum across various social platforms.

Planet Fitness, Inc. engages in the operation and franchising of fitness centers. It operates through the following segments: Franchise, Corporate-Owned Clubs, and Equipment. The Franchise segment includes operations related to the company's franchising business in the United States, Puerto Rico, Canada, Panama, Mexico, and Australia. The Corporate-Owned Clubs segment consists of operations with respect to all corporate-owned clubs throughout the United States, Canada, and Spain. The Equipment segment involves the sale of equipment to franchisee-owned clubs in the United States, Canada, and Mexico. The company was founded by Michael Grondahl and Marc Grondahl in 1992 and is headquartered in Hampton, NH.

Planet Fitness Inc - Ordinary Shares - Class A

Planet Fitness is under intense pressure as the company faces a growing community-led boycott and increased scrutiny following controversies over its locker room policies. Investors are debating the stock's valuation as the market watches to see if this reputational backlash and rising membership cancellations will meaningfully impact the company's long-term growth and financial outlook.

Churchill Downs, Inc. is a provider of pari-mutuel horse racing, online account wagering on horse racing and casino gaming. It operates through the following segments: Live and Historical Racing, Wagering Services and Solutions, and Gaming. The Live and Historical Racing segment includes live and historical pari-mutuel racing related revenue and expenses at Churchill Downs Racetrack and historical racing properties in Kentucky, Virginia, and New Hampshire. The Wagering Services and Solutions focuses on the revenue and expenses from pari-mutuel wagers through TwinSpires, retail and online sports betting business, United Tote Company, and Exacta Systems, LLC. The Gaming segment is involved in the casino properties and associated racetracks which support the casino license. The company was founded in 1875 and is headquartered in Louisville, KY.

Churchill Downs, Inc.

Churchill Downs is trending as investors weigh recent quarterly performance and strategic expansions against competitive pressures in the gaming and sports wagering sector. The community is actively discussing the company's growth trajectory and ongoing capital projects, alongside its relative valuation compared to other industry players.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The Zacks Analyst Blog Highlights IBB, XBI, BBH and GNOM

IBB and peers are gaining traction as AI transforms biotech, boosting drug discovery, trials and growth prospects across diversified ETF portfolios.

Beyond Tech Industry: Here's how Biotech ETFs Are Riding the AI Wave

IBB and other biotech ETFs are gaining traction as AI reshapes drug discovery, genomics, and clinical trials, giving investors diversified exposure to biotech innovation.

<ul class="summary-bullets"><li>CRISPR Therapeutics said the debt securities will rank as senior unsecured obligations.</li><li>Interest payments will be made twice each year, with the first scheduled payment expected in September 2026.</li><li>In January, the company said it had around $2 billion in cash, cash equivalents, and marketable securities.</li></ul>CRISPR Therapeutics AG (CRSP) on Tuesday announced plans to raise capital through a private debt offering as the gene-editing biotechnology company continues funding research and development efforts.&nbsp;The company said it intends to issue $350 million in convertible senior notes, scheduled to mature in 2031, subject to prevailing market conditions and investor demand.<h2 class="st-heading-2">Structure Of The Convertible Notes</h2>According to the company, the debt securities will rank as senior unsecured obligations.&nbsp;Interest payments will be made twice each year, with the first scheduled payment expected in September 2026.&nbsp;Unless the notes are converted into shares, repurchased, or redeemed earlier, they will come due on Mar. 1, 2031. If investors choose to convert the notes, CRISPR will settle the conversion by issuing common shares with a nominal value of CHF 0.03 ($0.039) each.CRISPR Therapeutics said it expects to allocate the net proceeds from the sale for broad corporate needs.&nbsp;<a href="https://stocktwits.com/symbol/CRSP">CRISPR Therapeutics stock</a> traded over 6% lower in Tuesday’s premarket.&nbsp;On Stocktwits, retail sentiment around the stock changed to ‘bullish’ from ‘bearish’ territory the previous day. Message volume flipped to ‘high’ from ‘low’ levels in 24 hours.&nbsp;<h2 class="st-heading-2">2026 Goals</h2>CRISPR Therapeutics is developing a wide range of programs in blood disorders, cancer, regenerative medicine, heart and autoimmune diseases, and other rare conditions. CASGEVY is the first CRISPR-based therapy for patients with sickle cell disease and transfusion-dependent beta thalassemia.In January, it&nbsp;outlined its strategic priorities for 2026, highlighting multiple expected milestones across its gene-editing and siRNA portfolios. It also emphasized a strong financial position, with around $2 billion in cash, cash equivalents, and marketable securities to support ongoing research and commercial activities.CRSP stock has gained over 23% in the last 12 months.&nbsp;Exchange Rate: 1CHF=1.29USDAlso See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/capr-stock-surged-today-what-is-fueling-the-rally/cZdovHXRI7O">CAPR Stock Surged 17% Today — What’s Fueling The Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Crispr Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Is CRSP Stock Falling Pre-Market Today?

CRISPR Therapeutics AG (CRSP) on Tuesday announced plans to raise capital through a private debt offering as the gene-editing biotechnology company continues funding research and development efforts. 

Why Is CRSP (CRISPR Therapeutics) Stock Falling Pre-Market Today?

Equity

The company plans to issue $350 million in convertible senior notes that are scheduled to mature in 2031.


<ul class="summary-bullets"><li>The German drugmaker will transfer select intellectual property to the new entity while retaining a minority stake.</li><li>The new entity will operate independently with its own financial structure, research agenda, and operational framework.</li><li>BioNTech will continue concentrating on its expanding late-stage development portfolio.</li></ul>BioNTech SE (BNTX) on Tuesday revealed plans to launch a separate biotechnology venture dedicated to advancing next-generation messenger RNA technologies, with the initiative to be led by its co-founders Ugur Sahin and Prof. Özlem Türeci, who are set to leave the company to head the new venture.&nbsp;&nbsp;The new entity will operate independently with its own financial structure, research agenda, and operational framework while collaborating with BioNTech in specific areas of development.Following the announcement, BioNTech stock tumbled nearly 17% in Tuesday’s premarket.&nbsp;On Stocktwits, retail sentiment around the stock remained in ‘extremely bullish’ territory amid ‘extremely high’ message volume levels.&nbsp;<h3>Founders Exit To Lead New mRNA Venture</h3>The Germany-based company intends to transfer certain intellectual property and technology assets tied to mRNA research to the new organization while retaining a minority ownership stake and potential milestone or royalty payments.The forthcoming company will concentrate exclusively on developing emerging mRNA platform technologies with potential medical applications.<h3>BioNTech Keeps Focus On Oncology Pipeline</h3>While the new venture focuses on experimental mRNA innovation, BioNTech will continue concentrating on its expanding late-stage development portfolio. The company expects around 15 Phase 3 clinical trials in oncology to be underway by the end of 2026.&nbsp;“We believe that this plan will be additive for both, BioNTech and the new company, as it aims to allow each organization to drive meaningful impact for patients”.-Helmut Jeggle, Chairman, BioNTech Supervisory Board<h2 class="st-heading-2">Q4 Earnings Pressure&nbsp;</h2>BioNTech reported a 23% year-on-year (YoY) decline in fourth-quarter earnings to €907.4 million ($1.05 billion). Loss per share also widened to €1.25 from a loss per share of €0.33 last year.&nbsp;BNTX stock has declined by 3% in the last 12 months.&nbsp;Conversion Rate: €1=$1.16Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/att-250-billion-fiber-5g-network-investment-plan/cZdoY58RIew">AT&amp;T Is Spending $250B On Connectivity In The US – Here’s Where The Money Is Going</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

BioNTech mRNA-based vaccine manufacturing site in Rwanda | Source: BioNTech

Why Did BNTX Stock Tumble 17% Pre-Market Today? 

BioNTech co-founders Ugur Sahin and  Özlem Türeci are set to leave the company to head the new venture.  

<ul class="summary-bullets"><li>Moderna has submitted a revised approach to streamline approval based on age-specific indications.</li><li>The company proposed a dual-pathway regulatory strategy, seeking full FDA approval for adults aged 50 to 64 and accelerated approval for adults 65 and older.</li><li>Last week, the FDA refused to review Moderna’s application for the flu vaccine.</li></ul>Moderna, Inc. (MRNA) said on Wednesday that it is moving forward with regulatory review for its investigational seasonal flu vaccine, mRNA-1010, after responding to a prior Refusal-to-File letter from the U.S. Food and Drug Administration (FDA).&nbsp;The company has submitted a revised approach to streamline approvals based on age-specific indications.<h2 class="st-heading-2">Targeted Approval Strategy</h2>Moderna proposed a dual-pathway regulatory strategy, seeking full FDA approval for adults aged 50 to 64 and accelerated approval for adults aged 65 and older, along with a post-marketing study to further evaluate safety and efficacy in older populations.The FDA has now accepted the biologics license application (BLA) for review, setting a Prescription Drug User Fee Act (PDUFA) goal date of Aug. 5, 2026.<blockquote>"Pending FDA approval, we look forward to making our flu vaccine available later this year so that America's seniors have access to a new option to protect themselves against flu."-Stéphane Bancel, CEO, Moderna</blockquote>Following the update,&nbsp;<a href="https://stocktwits.com/symbol/MRNA">Moderna’s stock</a> traded over 5% higher on Wednesday morning. On Stocktwits, retail sentiment around the stock jumped to ‘bullish’ from ‘neutral’ territory the previous day amid ‘high’ message volume.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_02_18_091941_png_316eca4dee.webp" alt="MRNA’s Sentiment Meter and Message Volume as of 09:50 a.m. ET on Feb. 18, 2026 | Source: Stocktwits" width="930" height="102"><figcaption>MRNA’s Sentiment Meter and Message Volume as of 09:50 a.m. ET on Feb. 18, 2026 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Global Regulatory Progress</h2>mRNA-1010 has entered regulatory review not only in the U.S. but also in Europe, Canada, and Australia, with additional filings planned for later in 2026. Moderna anticipates the first potential approvals for the vaccine to occur within the year.If approved, mRNA-1010 would be available for U.S. adults aged 50 and above, including those 65 and older, for the 2026/2027 influenza season.&nbsp;Last week, the FDA refused to review Moderna’s application for the flu vaccine and cited the lack of an "adequate and well-controlled" study with a comparator arm that "does not reflect the best-available standard of care."&nbsp;MRNA stock has gained over 28% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/walmart-earnings-can-wmt-stock-sustain-momentum-under-new-ceo/cZR0ZxRR4Hs">Walmart Earnings Ahead: Can WMT Stock Sustain Momentum Under New CEO?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Moderna’s logo is displayed on a smartphone with an economic stock exchange index graph in the background. (Photo Illustration by Budrul Chukrut/SOPA Images/LightRocket via Getty Images)

Moderna Stock Gains After FDA Accepts Company’s Revised Flu Vaccine Application For Review

The FDA has now accepted the biologics license application for review, setting a Prescription Drug User Fee Act goal date of Aug. 5, 2026.

Current Price	$45.97
Prev Close	$46.16
Open	$46.22
Dividend Yield	N/A
50-Day Moving Average	$45.24
Beta	N/A
Avg. Volume	11,910.92
PE Ratio	N/A

52-Week High	$51.42
52-Week Low	$29.44
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

GNOM
Global X Funds - Global X Genomics & Biotechnology ETF

Feed

News

Sentiment

Fundamentals

Info

Latest GNOM News

GNOMGlobal X Funds - Global X Genomics & Biotechnology ETF